Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 21;12(11):1150.
doi: 10.3390/metabo12111150.

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms

Affiliations
Review

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms

Xiaoyang Lan et al. Metabolites. .

Abstract

Obesity is a major burden for modern medicine, with many links to negative health outcomes, including the increased incidence of certain cancer types. Interestingly, some studies have supported the concept of an "Obesity Paradox", where some cancer patients living with obesity have been shown to have a better prognosis than non-obese patients. Neuroendocrine neoplasms (NENs) are malignancies originating from neuroendocrine cells, in some cases retaining important functional properties with consequences for metabolism and nutritional status. In this review, we summarize the existing evidence demonstrating that obesity is both a risk factor for developing NENs as well as a good prognostic factor. We further identify the limitations of existing studies and further avenues of research that will be necessary to optimize the metabolic and nutritional status of patients living with NENs to ensure improved outcomes.

Keywords: body mass index; neuroendocrine neoplasm; nutrition; obesity.

PubMed Disclaimer

Conflict of interest statement

X.L. declares no conflicts of interest. N.F. is an advisory board member of, or collects speaker fees from, Novartis, Ipsen, AAA, Hutchmed, Merck, MSD and Sanofi. O.A.-R. is an advisory board member of, or collects speaker fees from, Lilly, Roche, Eisai, Bayer, Ipsen and Amgen.

References

    1. Dixon J.B. The Effect of Obesity on Health Outcomes. Mol. Cell. Endocrinol. 2010;316:104–108. doi: 10.1016/j.mce.2009.07.008. - DOI - PubMed
    1. Riaz H., Khan M.S., Siddiqi T.J., Usman M.S., Shah N., Goyal A., Khan S.S., Mookadam F., Krasuski R.A., Ahmed H. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies. JAMA Netw. Open. 2018;1:e183788. doi: 10.1001/jamanetworkopen.2018.3788. - DOI - PMC - PubMed
    1. Bhupathiraju S.N., Hu F.B. Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications. Circ. Res. 2016;118:1723–1735. doi: 10.1161/CIRCRESAHA.115.306825. - DOI - PMC - PubMed
    1. Flegal K.M., Kit B.K., Orpana H., Graubard B.I. Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories: A Systematic Review and Meta-Analysis. JAMA. 2013;309:71. doi: 10.1001/jama.2012.113905. - DOI - PMC - PubMed
    1. The GBD 2015 Obesity Collaborators Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N. Engl. J. Med. 2017;377:13–27. doi: 10.1056/NEJMoa1614362. - DOI - PMC - PubMed

LinkOut - more resources